@book{oai:kanazawa-u.repo.nii.ac.jp:00014366,
 author = {Inazu, Akihiro},
 issue = {(Editors: Tsugikazu Komoda)},
 month = {Feb},
 note = {Although some CETP-lowering SNPs in the CETP gene are variably associated with improved clinical outcomes in patients with coronary artery disease (CAD), three low molecular weight oral CETP inhibitors (torcetrapib, dalcetrapib, and evacetrapib) have not shown any clinical benefits despite remarkable increases in HDL-cholesterol levels ranging 31-138%. Potential causes for that failure are discussed in terms of off-target effects of some inhibitors, potential misleading interpretation of genetic epidemiological surveys in CETP gene, and inadequate alteration in HDL function induced by the inhibitors. Possible modalities of CETP inhibition such as antisense nucleotides and monoclonal antibodies are discussed., A part of the book},
 publisher = {Academic Press / Elsevier},
 title = {CETP deficiency and concerns in CETP inhibitor development},
 volume = {Jan 7, 2016},
 year = {2017}
}